Almirall starts marketing Skilarence in Europe

Almirall (ALM: MC) is starting to market Skilarence(dimethyl fumarate), a new oral formulation of DMF developed by the company which is indicated as a first-line induction and long-term maintenance therapy for patients with moderate-to-severe chronic plaque psoriasis.

It is the first and only fumaric acid ester (FAE) approved by the European Commission (in June 2017) for the treatment of adults with psoriasis in need of systemic medicinal therapy, constituting a new option for a larger number of patients with the disease, noted Almirall, Spain’s largest drugmaker.

According to Bhushan Hardas, Almirall’s executive vice president R&D and chief scientific officer, “the launch of Skilarenceresponds to Almirall’s aim to find innovative solutions to fight psoriasis, a disease that affects 125 million people worldwide.” From his part, Rajesh Gupta, global marketing dermatology director at Almirall, explained that “this product will provide a new cost-effective option to patients with psoriasis welcomed by healthcare providers and payers in EU countries, Iceland and Norway.”